| Transport Package: | Carton |
|---|---|
| Specification: | 40mg |
| Trademark: | Focus |
| Origin: | China |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Product name | Esomeprazole for injection |
| Main Ingredients | Esomeprazole |
| Adaptation disease | As an alternative therapy for gastroesophageal reflux disease when oral therapy is not available. This product should normally be taken for a short period of time (not exceeding 7 days) and switched to oral therapy as soon as possible. |
| Dosage form | powder-injection |
| Character | This product is a white or quasi-white freeze-dried lump or powder. |
| Specification | 40mg |
| Usage and dosage | 1. For patients who cannot take the drug orally, it is recommended to inject 20-40mg intravenously or intravenously once a day. Patients with reflux esophagitis should take 40mg, once a day; Symptoms of reflux disease should be treated with 20mg, once daily. 2, For injection: 40mg and 20mg solution should be injected intravenously within at least 3 minutes. 3,Intravenous infusion: 40mg and 20mg solution should be intravenous infusion within 10 to 30 minutes. 4. Use instructions Injection is prepared by adding 5ml 0.9% sodium chloride solution into vials for intravenous administration. The infusion solution was prepared by dissolving one dose of the product into 0.9% sodium chloride solution 100ml for intravenous infusion. The prepared liquid for injection or infusion is a clear colorless and extremely yellowish solution, which should be used within 12 hours and kept below 30ºC. It is best to use it immediately from a microbiological point of view. 5. Incompatibility Degradation of formulated solutions is highly pH dependent, so the product must be applied as directed. This product can only be dissolved in 0.9% sodium chloride for intravenous use. The prepared solution should not be mixed with other drugs or used in the same infusion device. |
| Storage | Keep airtight in cool dark place (not more than 20ºC from light) |
| Origin | China |
| Validity | 24 months |
| Tatoo | 1. When a patient is suspected of having or having a gastric ulcer, malignant tumor should be ruled out if there are abnormal symptoms (such as significant unintentional weight loss, recurrent vomiting, difficulty swallowing, vomiting blood, or black stools). Treatment with this product can relieve symptoms and delay diagnosis. 2. Patients with renal impairment need not adjust the dose. Due to limited experience with this product in patients with severe renal insufficiency, caution should be exercised in its treatment (see [pharmacokinetics]). 3. Patients with mild to moderate liver damage do not need to adjust the dose. The daily dose should not exceed 20mg in patients with severe liver impairment (see [pharmacokinetics]). 4. Effects on driving and ability to use machinery: No effects have been observed. |
| Notice | The following adverse reactions have been identified or suspected in clinical trials of esomeprazole oral or intravenous administration and in post-marketing studies of oral administration. These reactions are divided into the following categories according to the frequency of occurrence (common >1%, 0.1%, 0.01%, <0.1%; Very rare <0.01%). 1. Eyes: Occasionally: Blurred vision. 2. Ear and lost: Occasionally: Vertigo. 3. Skin and subcutaneous tissue: occasionally: dermatitis, pruritus, rash, urticaria; Rare: hair loss, photosensitivity; Very rare: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN). 4. Skeletal muscle, connective tissue, and bone: Rare: joint pain, myalgia: Very rare: muscle weakness. 5. Respiration, chest, mediastinum: rare: bronchospasm. 6. Digestive system: Common: abdominal pain, constipation, diarrhea, abdominal distension, nausea/vomiting; Occasionally: dry mouth; Rare: stomatitis, gastrointestinal candidiasis. 7. Hepatobiliary system: rare: elevated liver enzymes: rare: hepatitis with or without jaundice; Very rare: encephalopathy in patients with liver failure or prior liver disease. 8. Kidney and urinary system: very rare: interstitial nephritis. 9. Blood and lymphatic system: rare: leukopenia, thrombocytopenia: Very rare: granulocytosis, pancytopenia. 10. Immune system: Rare: hypersensitive reactions such as fever, angioedema and anaphylaxis/shock. 1. Metabolic and nutritional disorders (available only for medical professionals on request for details) : Occasional: peripheral 12. Edema; Rare: hyponatremia. 13. Nervous system: Common: headache: occasionally: dizziness, paresthesia, lethargy; Rare: taste disorder. Mental state: Occasionally: insomnia; Rare: agitation, confusion, depression; Very rare: attacks, hallucinations. 14. Reproductive system and breasts: Very rare: male-female breasts. 15. Administration site and general discomfort: rare: discomfort, sweating. Irreversible visual impairment has been reported in critically ill patients receiving intravenous omeprazole racemate, especially at high doses, but causality has not been established. |
This product is a white or quasi-white loose block or powder, the main ingredient is esomeprazole, belongs to the powder, please keep in a cool dark place (avoid light not more than 20ºC) sealed.
This product is used primarily as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis and Zollinger-Ellison syndrome when oral therapy is not applicable.
The specification of this product is 40mg, the packaging is controlled antibiotic glass bottle + medical halogenated butyl rubber stopper, glass bottle color can choose colorless or brown.
We can offer the following packages:
1 bottle/box, 2 bottles/box, 5 bottles/box, 6 bottles/box, 10 bottles/box, 20 bottles/box;
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}